BUDAPEST, Hungary, April 15, 2024 /PRNewswire/ -- At the 32^nd Annual Meeting of the European Psychiatric Association (6-9^th April, Budapest, Hungary) new analyses of cariprazine studies were presented by Gedeon Richter Plc. The scientific posters proved that cariprazine might be an appropriate treatment not only for early and late-stage schizophrenia, but also for the difficult-to-treat dual disorder (schizophrenia and comorbid substance use disorder). Furthermore, a new transdiagnostic tool for quantifying, and visualizing symptom severity and functional disability of patients with different psychiatric conditions was presented. A special Gedeon Richter publication, the "Candid Book" was also introduced by the authors, which contains useful, everyday suggestions for the caregivers of patients.

The first Richter poster at the congress provided evidence that cariprazine is effective in treating patients with late-stage schizophrenia, while the second poster focused on the early stage of schizophrenia (illness duration of less than 5 years) and the impact of cariprazine in preventing relapse. According to the results, the relative risk of relapse was reduced by 81%. In the third poster, views of patients and doctors regarding predominant negative symptoms were compared during a 1-year observational study. The final poster was providing information on the potential of cariprazine in dual disorder, the co-occurrence of a major psychiatric disorder and comorbid substance use disorder. Evidence suggests that cariprazine is a potential candidate for treatment as it improves symptoms of both disorders: patients experienced improvement in their anxiety, mood, psychotic symptoms, along with reduction in craving and substance consumption.

In addition, Richter organized two scientific sessions: the Product Theatre focused on the topic of "New treatment options for dual schizophrenia", and a Mini Symposium was organized on the topic of "Schizophrenia and the management of psychiatric comorbidities", such as affective, anxiety and substance use disorders.

On the 7^th of April, during a Scientific Event involving over 250 doctors, Professor Christoph U. Correll highlighted the importance of using measurements in everyday psychiatric practice, and experts from Gedeon Richter launched a new transdiagnostic tool for quantifying, and visualizing symptom severity and functional disability of patients with different psychiatric conditions which is available online. During the time of the conference, Richter's Candid Book - a comprehensive summary of important topics that responds to caregivers' needs in real life situations - was also presented to the professional audience.

About Richter

About Cariprazine

View original content:https://www.prnewswire.co.uk/news-releases/gedeon-richter-cariprazine-shows-effectiveness-in-the-treatment-for-dual-disorder-302115698.html

Tags

More Like This

Gedeon Richter: Cariprazine shows effectiveness in the treatment of mental health disorders with combined substance use disorder

Gedeon Richter: A new hope for treatment-resistant schizophrenia?

Gedeon Richter: an effective treatment for female schizophrenia patients

Gedeon Richter presents analysis on cannabis usage among patients with schizophrenia: a new medical solution to a severe issue might be available

Gedeon Richter: Cariprazine has a real chance of becoming the best-selling atypical antipsychotic drug

Gedeon Richter: Medical Treatment of Endometriosis with a progressive approach

Side-by-Side Conference Hosts Close to 800 Participants in Malta to Advance Women's Health Care

Rxulti® (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older